Metabolic Syndrome and Prostate Cancer Risk: A Population Case-control Study.
Arch Med Res
; 53(6): 594-602, 2022 09.
Article
em En
| MEDLINE
| ID: mdl-35909002
BACKGROUND: Metabolic syndrome (MS) with mixed dyslipidemia and prostate cancer (PC) are relevant health problems among Mexican men. However, there is no information regarding the association between MS and PC for this population. AIM OF THE STUDY: To evaluate this association in a population case-control study in Mexico City. METHODS: We analyzed the information from 394 incident PC-cases and 793 population age-matched (± 5 years) controls, identified in Mexico City (2011-2014). For cases, Gleason score at diagnosis was available. We defined MS history based on the self-report of hypertension, hypercholesterolemia, hypertriglyceridemia, and diabetes; obesity was evaluated using weight-change trajectories throughout life. In addition, the four MS-typologies described for Mexican population were used. The association between MS with PC and histological PC differentiation was evaluated using independent multivariate logistic regression models. RESULTS: MS history was associated with a high PC probability (OR 1.94; 95% CI 1.37-2.75). Lipid alterations, arterial hypertension, and a marked weight increase throughout life were associated with increased PC probability; however, only the marked weight increase was associated with more poorly differentiated PC (Gleason ≥8) (OR 2.79; 95% CI 1.50-5.17). CONCLUSION: Like other populations, in this Mexican study, MS and some of its components were identified as potential PC risk factors. MS-lipid alteration typology seems to be relevant; however, the novelty of this approach together with the retrospective nature of this study, indicate that a prospective evaluation of the MS typologies and PC association must be performed.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Síndrome Metabólica
/
Hipertensão
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article